Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Germany
- Extension of Reference Pricing to Patent-Protected Drugs
- A More Aggressive Reference Price Method
- Incentives to Undercut Reference Prices
- Price Adjustments in 2007
- Market Impact
- Netherlands
- Spain
- Italy
- France
- Outlook and Implications for the Pharmaceutical Industry
Sidebars
- The Impact of Generics Competition and Reference Pricing on the German
Statin Market-A Cautionary Tale
- To Cut or Not to Cut-The Pros and Cons of Reference Price Alignment
- German Physicians' Views on Reference Pricing-Lessons from the Statin
Market
Tables
- 1. Out-of-Pocket Payments for Reference-Priced Drugs in Germany
- 2. Cumulative Savings from Reference Pricing in Germany, 1989-2007
- 3. Penetration of Reference-Priced Drugs into the German Pharmaceutical
Market, 2004-2006
- 4. Drugs Exceeding Their Reference Prices in France (June 1, 2005)
Figures
- 1. Reference-Priced Drugs in Germany: Percentage of Drugs with Retail
Prices Above, In Line With, and Below Their Respective Reference Prices
(January 1, 2007)
- 2. Total Sales and Prescription Shares of Reference-Priced Drugs in the
German Statutory Health Insurance Pharmaceutical Market, 1999-2005
- 3. Reference-Priced Drugs in Spain: Overall Relationship Between Drug
Prices and Their Reference Prices
- A. Consumption of Statins in the German Statutory Health Insurance Market,
2001-2005
- B. Proton Pump Inhibitors in the German Statutory Health Insurance
Pharmaceutical Market: Percentage Change in Price, Prescribing Volume, and
Sales (2004-2005)
- C. Sartans in the German Statutory Health Insurance Pharmaceutical Market:
Percentage Change in Price, Prescribing Volume, and Sales (2004-2005)
- D. Has Reference Pricing Created a Two-Class System for the Treatment of
Dyslipidemia in Germany? (Physician Responses)
- E. Physician Views of Actions Taken by GKV Patients Prescribed
Atorvastatin in 2005
|
Related Report
|
View Cart
